Yusuke Okuno

Yusuke Okuno

Auto-generated profile, based on publicly available information

Yusuke Okuno

Department of Virology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2013 in Leukemia
Verified
Journal Article
Open access
PDF file
THT Haferlach
T Haferlach
YNY Nagata
Y Nagata
VGV Grossmann
V Grossmann
YOY Okuno
Y Okuno
UBU Bacher
U Bacher
SOSeishi Ogawa
Seishi Ogawa
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological and prognostic significance of genetic aberrations in MDS. In total, 944 patients with various MDS subtypes were screened for known/putative mutations/deletions in 104 genes using targeted deep sequencing and array-based genomic hybridization. In total, 845/944 patients (89.5%) harbored at least one mutation (median, 3 per patient; range, 0–12). Forty-seven genes were significantly mutated with TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 mutated in >10% of cases. Many mutations were associated with higher risk groups and/or blast elevation. Survival was investigated in 875 patients. By univariate analysis, 25/48 genes (resulting from 47 genes tested significantly plus PRPF8) affected survival (P<0.05). The status of 14 genes combined with conventional factors revealed a novel prognostic model (‘Model-1’) separating patients into four risk groups (‘low’, ‘intermediate’, ‘high’, ‘very high risk’) with 3-year survival of 95.2, 69.3, 32.8, and 5.3% (P<0.001). Subsequently, a ‘gene-only model’ (‘Model-2’) was constructed based on 14 genes also yielding four significant risk groups (P<0.001). Both models were reproducible in the validation cohort (n=175 patients; P<0.001 each). Thus, large-scale genetic and molecular profiling of multiple target genes is invaluable for subclassification and prognostication in MDS patients.

24 June 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
YSYusuke Sato
Yusuke Sato
TYTetsuichi Yoshizato
Tetsuichi Yoshizato
YSYuichi Shiraishi
Yuichi Shiraishi
SMShigekatsu Maekawa
Shigekatsu Maekawa
YOYusuke Okuno
Yusuke Okuno
SOSeishi Ogawa
Seishi Ogawa

12 January 2014 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MSMamiko Sakata-Yanagimoto
Mamiko Sakata-Yanagimoto
TETerukazu Enami
Terukazu Enami
KYKenichi Yoshida
Kenichi Yoshida
YSYuichi Shiraishi
Yuichi Shiraishi
RIRyohei Ishii
Ryohei Ishii
SCShigeru Chiba
Shigeru Chiba

2 July 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TYTetsuichi Yoshizato
Tetsuichi Yoshizato
BDBogdan Dumitriu
Bogdan Dumitriu
KHKohei Hosokawa
Kohei Hosokawa
HMHideki Makishima
Hideki Makishima
KYKenichi Yoshida
Kenichi Yoshida
SOSeishi Ogawa
Seishi Ogawa
In patients with acquired aplastic anemia, destruction of hematopoietic cells by the immune system leads to pancytopenia. Patients have a response to immunosuppressive therapy, but myelodysplastic syndromes and acute myeloid leukemia develop in about 15% of the patients, usually many months to years after the diagnosis of aplastic anemia. We performed next-generation sequencing and array-based karyotyping using 668 blood samples obtained from 439 patients with aplastic anemia. We analyzed serial samples obtained from 82 patients. Somatic mutations in myeloid cancer candidate genes were present in one third of the patients, in a limited number of genes and at low initial variant allele frequency. Clonal hematopoiesis was detected in 47% of the patients, most frequently as acquired mutations. The prevalence of the mutations increased with age, and mutations had an age-related signature. DNMT3A-mutated and ASXL1-mutated clones tended to increase in size over time; the size of BCOR- and BCORL1-mutated and PIGA-mutated clones decreased or remained stable. Mutations in PIGA and BCOR and BCORL1 correlated with a better response to immunosuppressive therapy and longer and a higher rate of overall and progression-free survival; mutations in a subgroup of genes that included DNMT3A and ASXL1 were associated with worse outcomes. However, clonal dynamics were highly variable and might not necessarily have predicted the response to therapy and long-term survival among individual patients. Clonal hematopoiesis was prevalent in aplastic anemia. Some mutations were related to clinical outcomes. A highly biased set of mutations is evidence of Darwinian selection in the failed bone marrow environment. The pattern of somatic clones in individual patients over time was variable and frequently unpredictable. (Funded by Grant-in-Aid for Scientific Research and others.)

30 March 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
Dechen LinDechen Lin
Dechen Lin
JHJia-Jie Hao
Jia-Jie Hao
YNYasunobu Nagata
Yasunobu Nagata
Liang XuLiang Xu
Liang Xu
LSLi Shang
Li Shang
HKH Phillip Koeffler
H Phillip Koeffler
De-Chen Lin, Ming-Rong Wang and colleagues report exome sequencing, RNA sequencing, and copy number analyses of esophageal squamous cell carcinoma. They identified recurrent mutations in FAT1, FAT2, ZNF750, EP300 and KMT2D. Esophageal squamous cell carcinoma (ESCC) is prevalent worldwide and particularly common in certain regions of Asia. Here we report the whole-exome or targeted deep sequencing of 139 paired ESCC cases, and analysis of somatic copy number variations (SCNV) of over 180 ESCCs. We identified previously uncharacterized mutated genes such as FAT1, FAT2, ZNF750 and KMT2D, in addition to those already known (TP53, PIK3CA and NOTCH1). Further SCNV evaluation, immunohistochemistry and biological analysis suggested their functional relevance in ESCC. Notably, RTK-MAPK-PI3K pathways, cell cycle and epigenetic regulation are frequently dysregulated by multiple molecular mechanisms in this cancer. Our approaches also uncovered many druggable candidates, and XPO1 was further explored as a therapeutic target because it showed both gene mutation and protein overexpression. Our integrated study unmasks a number of novel genetic lesions in ESCC and provides an important molecular foundation for understanding esophageal tumors and developing therapeutic targets.

18 August 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AKAyana Kon
Ayana Kon
LSLee-Yung Shih
Lee-Yung Shih
MMMasashi Minamino
Masashi Minamino
MSMasashi Sanada
Masashi Sanada
YSYuichi Shiraishi
Yuichi Shiraishi
SOSeishi Ogawa
Seishi Ogawa